No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 10,314 | 14,917 | 15,934 | 15,117 | 21,610 | 22,251 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 3,564 | 4,356 | 3,620 | 2,704 | 5,869 | 6,764 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Zhejiang NHU Company Ltd., founded in 1999 and headquartered in Xinchang, China, specializes in the nationwide production and distribution of a broad spectrum of chemical products. Its principal operations are divided into four main categories: 1. Nutritional Products: The company offers a comprehensive range of supplements, including essential vitamins (E, A, C, D3, biotin), DL-Methionine, coenzyme Q10, and various carotenoids. These ingredients are critical for enhancing animal feed and fortifying food, beverages, and health-related products. 2. Flavors and Fragrances: This segment supplies a variety of aroma chemicals, such as derivatives from the linalool and citral series, cis-3-hexenol, methyl dihydrojasmonate, raspberry ketone, and ligustral, which are widely utilized in personal care items, cosmetic formulations, and food flavorings. 3. New Polymer Materials: Zhejiang NHU provides advanced polymer solutions like polyphenylene sulfide and polyphthalamide. These materials find essential applications across industries including electronics, automotive manufacturing, and environmental protection. 4. Active Pharmaceutical Ingredients (APIs): The company manufactures crucial pharmaceutical components, including moxifloxacin hydrochloride, vitamin A, and vitamin D3, which serve as foundational substances for the development and production of various drug preparations.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Zhejiang NHU Company Ltd. (002001.SZ)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Zhejiang NHU Company Ltd., founded in 1999 and headquartered in Xinchang, China, specializes in the nationwide production and distribution of a broad spectrum of chemical products. Its principal operations are divided into four main categories: 1. Nutritional Products: The company offers a comprehensive range of supplements, including essential vitamins (E, A, C, D3, biotin), DL-Methionine, coenzyme Q10, and various carotenoids. These ingredients are critical for enhancing animal feed and fortifying food, beverages, and health-related products. 2. Flavors and Fragrances: This segment supplies a variety of aroma chemicals, such as derivatives from the linalool and citral series, cis-3-hexenol, methyl dihydrojasmonate, raspberry ketone, and ligustral, which are widely utilized in personal care items, cosmetic formulations, and food flavorings. 3. New Polymer Materials: Zhejiang NHU provides advanced polymer solutions like polyphenylene sulfide and polyphthalamide. These materials find essential applications across industries including electronics, automotive manufacturing, and environmental protection. 4. Active Pharmaceutical Ingredients (APIs): The company manufactures crucial pharmaceutical components, including moxifloxacin hydrochloride, vitamin A, and vitamin D3, which serve as foundational substances for the development and production of various drug preparations.